Vespro GHS CFS Clinical Trial
A CLINICAL TRIAL OF VESPRO GROWTH HORMONE SECRETAGOGUE IN PERSONS WITH CHRONIC FATIGUE SYNDROME
Salvato, P., Thompson, C., Bayou City Medical Center Hospital, Houston, Texas, USA
To determine if a growth hormone secretagogue called SomatoMed (VesPro GHS Growth Hormone) was safe and efficacious in patients with CDC defined Chronic Fatigue Syndrome (CFS).
Body cell mass measured by BIA (BCM) natural killer number (NK#), and Insulin growth factor-1 (IgF-1) levels were evaluated in 20 CFS patients. These measures were assessed at study initiation and monthly for two months. Subjective measure of symptoms, cognitive function, activities, of daily living and sleep disturbance were also assessed monthly for two months.
BCM: 55% patients had increase in BCM (muscle) of 1 lb. or more;
35% patients lost weight due to decrease in fat body mass;
10% patients gained muscle from 5 - 11 lbs;
IgF-1: 85% patients had increase in their IgF-1 level of 20% or more;
NK#: 80% patients had increase of their NK# of 30% or more;
Sleep: 80% patients had marked improvement in their sleep;
Cognitive: 75% patients had marked improvement in cognitive function'
Muscle Pain: 60% patients had improvement in muscle pain;
Fatigue: 90% patients had improvement in fatigue;
Side Effects: 45% patients had transient muscle and joint pain during initiation of therapy; 40% patients had mild edema;
An oral secretagogue, VesPro GHS, has been found to be safe and efficacious therapy; capable of improving many of the clinical signs and symptoms associated with the Chronic Fatigue Syndrome. Clinically, the efficacy of SomatoMed has been verified through IgF-1 measurements and patient assessment, as well as improvement in immune function and body cell mass. It is of interest to note that even in patients who did not raise IgF-1 levels, significant improvement in sleep and cognition were still noted. This product deserves further study in patients with Chronic Fatigue Syndrome.